echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The first subject enrolled in the Phase III clinical trial of Yuandong Bio-Udagliptin in the treatment of type 2 diabetes mellitus

    The first subject enrolled in the Phase III clinical trial of Yuandong Bio-Udagliptin in the treatment of type 2 diabetes mellitus

    • Last Update: 2022-03-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 15, Yuandong Biological announced that its self-developed Class 1 new drug Eudagliptin Tablets (hereinafter referred to as "Udagliptin Tablets") is being used as a single drug for the treatment of type 2 diabetes mellitus in China that is poorly controlled by simple diet and exercise.
    In the large-scale phase III clinical study of patients, the first subject has been successfully enrolled for administration recently
    .

    Eudagliptin is a dipeptidyl peptidase-IV (DPP-4) inhibitor, which has good hypoglycemic effect and excellent safety, and has been gradually accepted by clinicians and patients
    .


    Eudagliptin Tablets is a new class 1 chemical drug independently developed by the company and is the first oral DPP-4-week preparation for the treatment of type 2 diabetes in China


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.